secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001140361-24-008700
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q4 revenue $325M, up 114%; WAINUA approved; 2024 guidance: revenue >$575M
-------------------------------------------------------------------------------

- Q4 total revenue $325M (up 114% YoY); full year revenue $788M (up 34%); Q4 operating loss narrowed to $6M from $208M.
- WAINUA (eplontersen) FDA-approved for ATTRv-PN; U.S. launch underway; $50M milestone from AstraZeneca.
- Positive Phase 3 data for olezarsen (FCS) and donidalorsen (HAE); preparing regulatory submissions.
- 2024 guidance: revenue >$575M, non-GAAP operating loss <$475M, cash ~$1.7B.
- SPINRAZA royalties $240M in 2023; QALSODY royalties included; pipeline milestones with bepirovirsen, ION582.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124008700/0001140361-24-008700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124008700/ef20022046_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-008700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer